Therapy Areas: Autoimmune
Xencor reports financial results for 2018
26 February 2019 -

Xencor Inc (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, announced yesterday its financial results for the full year ended 31 December 2018.

The company reported total revenue of USD40.6m in 2018 compared to USD46.2m in the 2017.

The firm posted research and development expenditures for 2018 at USD97.5m compared to USD71.8m in 2017. For the year ended 31 December 2018, net loss was USD70.4m, or USD1.31 on a fully diluted per share basis, compared to a net loss of USD38.5m, or USD0.82 on a fully diluted per share basis, for the same period in 2017. The company stated that increased loss for the year ended 31 December 2018 over amounts for the same period in 2017 is primarily due to increased spending in research and development and general and administrative in 2018.

Login
Username:

Password: